ABL1 and breast carcinoma: ABL1, a non-receptor tyrosine kinase, has been implicated in response to DNA-damaging chemotherapeutics in tissue culture [28], while high expression of the centrosomal protein CENPF has been associated with good chemoresponses in breast cancers [29].